HopeStage
Back to all studies
CompletedNCT00829881

Betahistine for focus and attention in adults with ADHD

About this titleRead the official source — NCT00829881
Medication studyAges 22–55United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 22 years to 55 years.

Listed locations
CincinnatiSee all locations and recruitment
Participation duration
About 4 weeks
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJanuary 2009
Recruitment status
Completed
Enrollment listed in the registry
16
Sponsor
P2D, Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 22 Years to 55 Years
Official registry ID
NCT00829881
Official title
Show the full official title

Betahistine: Novel Therapeutic in Attention Deficit Hyperactivity Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Cincinnati

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is P2D, Inc.

Did this study involve medication?

Yes. The study involved medication, including Betahistine Hydrochloride and Placebo Capsule.

Who was this study for?

Listed age limits: 22 years to 55 years.

Want to explore more studies?

Explore studies